Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pathology & Oncology Research
Published in: Pathology & Oncology Research 3/2013

01-07-2013 | Research

A-Kinase Anchoring Proteins 10 Expression in Relation to 2073A/G Polymorphism and Tumor Progression in Patients with Colorectal Cancer

Authors: Mojin Wang, Dan Zhang, Rui Wang, Yuanyi Rui, Jin Zhou, Rong Wang, Bin Zhou, Xiaoran Huang, Lie Yang, Yuan Li, Jiankun Hu, Zongguang Zhou, Xiaofeng Sun

Published in: Pathology & Oncology Research | Issue 3/2013

Login to get access

Abstract

The cAMP/PKA signalling events regulated by A-kinase anchoring proteins 10 (AKAP10) is involved in tumorigenesis. Previous study showed that AKAP10 polymorphism (2073 A/G, I646V) was associated with colorectal cancer risk. However, there was no literature reporting the role of AKAP10 in the pathogenesis of colorectal cancer. The aim of the study was to investigate the clinicopathologic significance of A-kinase anchoring proteins 10 (AKAP 10) expression and the relationship with its polymorphism in colorectal cancer. The expression of AKAP10 was determined by immunohistochemical staining (IHC) and western blot assay on colorectal cancer (n = 176), adenoma (n = 87) and distant normal mucosa (n = 72). 176 patients with colorectal cancer were genotyped for AKAP10 2073A/G polymorphism by TaqMan RT-PCR. We found that the positive expression rate of AKAP10 in colorectal cancer (59 %) was significantly higher than those in adenoma (39 %) and distant normal mucosa (42 %) (P = 0.004). There was no significant difference between adenoma and distant normal mucosa (P = 0.741). Positive AKAP10 staining was correlated with deeper tumor invasion (P < 0.001), lymph nodes metastasis (P = 0.022), advanced tumor stage (P < 0.001) and poorly differentiated degree (P = 0.003). Compared with AA genotype (52 %), positive expression of AKAP10 was significantly increased in colorectal cancer patients with the variant (AG+GG) genotypes (68 %, P = 0.033). It was concluded that AKAP10 may play an important role in the development and progression of colorectal cancer.
Literature
1.
Vogelstein B, Fearon ER, Hamilton SR et al (1988) Genetic alterations during colorectal-tumor development. N Engl J Med 319:525–532PubMedCrossRef
2.
Cho YS, Park YG, Lee YN et al (2000) Extracellular protein kinase A as a cancer biomarker: its expression by tumor cells and reversal by a myristatelacking Ca and RIIβ subunit overexpression. Proc Natl Acad Sci USA 97:835–840PubMedCrossRef
3.
Wong W, Scott JD (2004) AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol 5:959–970PubMedCrossRef
4.
Huang L, Durick K, Weiner JA, Chun J, Taylor SS (1997) D-AKAP2, a novel protein kinase A anchoring protein with a putative RGS domain. Proc Natl Acad Sci USA 94:11184–11189PubMedCrossRef
5.
Hamuro Y, Burns L, Canaves J, Hoffman R, Taylor SS, Woods V (2002) Domain organization of D-AKAP2 revealed by enhanced deuterium exchange-mass spectrometry (DXMS). J Mol Biol 321:703–714PubMedCrossRef
6.
Sheng M, Sala C (2001) PDZ domains and the organization of supramolecular complexes. Annu Rev Neurosci 24:1–29PubMedCrossRef
7.
Wang L, Sunahara RK, Krumins A et al (2001) Cloning and mitochondrial localization of full-length D-AKAP2, a protein kinase A anchoring protein. Proc Natl Acad Sci USA 98:3220–3225PubMedCrossRef
8.
Burns-Hamuro LL, Barraclough DM, Taylor SS (2004) Identification and functional analysis of dual-specific A kinase-anchoring protein-2. Methods Enzymol 390:354–374PubMedCrossRef
9.
Neary CL, Nesterova M, Cho YS, Cheadle C, Becker KG, Cho-Chung YS (2004) Protein kinase A isozyme switching: eliciting differential cAMP signaling and tumor reversion. Oncogene 23:8847–8856PubMedCrossRef
10.
Cross TG, Scheel-Toellner D, Henriquez NV, Deacon E, Salmon M, Lord JM (2000) Serine/threonine protein kinases and apoptosis. Exp Cell Res 256:34–41PubMedCrossRef
11.
Tasken K, Skalhegg BS, Tasken KA et al (1997) Structure, function, and regulation of human cAMP-dependent protein kinases. Adv Second Messenger Phosphoprotein Res 31:191–204PubMedCrossRef
12.
Wirtenberger M, Schmutzhard J, Hemminkil K et al (2007) The functional genetic variant Ile646Val located in the kinase binding domain of the A-kinase anchoring protein 10 is associated with familial breast cancer. Carcinogenesis 28:423–426PubMedCrossRef
13.
Wang MJ, Zhou ZG, Wang L et al (2009) The Ile646Val (2073A>G) Polymorphism in the kinase-binding domain of A-kinase anchoring protein 10 and the risk of colorectal cancer. Oncology 76:199–204PubMedCrossRef
14.
Compton CC, Greene FL (2004) The staging of colorectal cancer: 2004 and beyond. CA Cancer J Clin 54:295–308PubMedCrossRef
15.
Yang L, Zhang H, Zhou ZG, Yan H, Adell G, Sun XF (2011) Biological function and prognostic significance of peroxisome proliferator-activated receptor δ in rectal cancer. Clin Cancer Res 17:3760–3770PubMedCrossRef
16.
Dodge-Kafka KL, Soughayer J, Pare GC et al (2005) The protein kinase A anchoring protein mAKAP coordinates two integrated cAMP effector pathways. Nature 437:574–578PubMedCrossRef
17.
Bradbury AW, Carter DC, Miller WR, Cho-Chung YS, Clair T (1994) Protein kinase A (PKA) regulatory subunit expression in colorectal cancer and related mucosa. Br J Cancer 69:738–742PubMedCrossRef
18.
Bold RJ, Alpard S, Ishizuka J, Townsend CM Jr, Thompson JC (1994) Growth-regulatory effect of gastrin on human colon cancer cell lines is determined by protein kinase a isoform content. Regul Pept 53:61–70PubMedCrossRef
19.
Nesterova MV, Johnson N, Cheadle C et al (2006) Autoantibody cancer biomarker: extracellular protein kinase A. Cancer Res 66:8971–8974PubMedCrossRef
20.
Hensley HH, Hannoun-Levi JM, Hachem P et al (2011) PKA knockdown enhances cell killing in response to radiation and androgen deprivation. Int J Cancer 128:962–973PubMedCrossRef
21.
Chen TC, Hinton DR, Zidovetzki R, Hofman FM (1998) Upregulation of the cAMP/PKA pathway inhibits proliferation, induces differentiation, and leads to apoptosis in malignant gliomas. Lab Invest 78:165–174PubMed
22.
Siddappa R, Mulder W, Steeghs I et al (2009) cAMP/PKA signaling inhibits osteogenic differentiation and bone formation in rodent models. Tissue Eng Part A 15:2135–2143PubMedCrossRef
23.
Loniewska B, Clark JS, Kaczmarczyk M et al (2012) Possible counter effect in newborns of 1936A>G (I646V) polymorphism in the AKAP10 gene encoding A-kinase-anchoring protein 10. J Perinatol 32:230–234PubMedCrossRef
24.
Zukowski M, Bohatyrewicz R, Biernawska J et al (2009) Association of the A1936G (rs203462) of A-kinase anchoring protein 10 polymorphisms with QT interval prolongation during kidney transplantation. Transplant Proc 41:3036–3038PubMedCrossRef
25.
Kammerer S, Burns-Hamuro LL, Ma Y et al (2003) Amino acid variant in the kinase binding domain of dual-specific A kinase-anchoring protein 2: a disease susceptibility polymorphism. Proc Natl Acad Sci USA 100:4066–4071PubMedCrossRef
Metadata
Title
A-Kinase Anchoring Proteins 10 Expression in Relation to 2073A/G Polymorphism and Tumor Progression in Patients with Colorectal Cancer
Authors
Mojin Wang
Dan Zhang
Rui Wang
Yuanyi Rui
Jin Zhou
Rong Wang
Bin Zhou
Xiaoran Huang
Lie Yang
Yuan Li
Jiankun Hu
Zongguang Zhou
Xiaofeng Sun
Publication date
01-07-2013
Publisher
Springer Netherlands
Published in
Pathology & Oncology Research / Issue 3/2013
Print ISSN: 1219-4956
Electronic ISSN: 1532-2807
DOI
https://doi.org/10.1007/s12253-013-9612-6

Other articles of this Issue 3/2013

Pathology & Oncology Research 3/2013 Go to the issue

Research

Treatment Response to Preoperative Anthracycline-Based Chemotherapy in Locally Advanced Breast Cancer: The Relevance of Proliferation and Apoptosis Rates

Review

Multicentric Castleman’s Disease: A Challenging Diagnosis

Research

Measurement of HER2 in Saliva of Women in Risk of Breast Cancer

Research

MicroRNA-335 Acts as a Candidate Tumor Suppressor in Prostate Cancer

Research

Anthracycline Causes Impaired Vascular Endothelial Function and Aortic Stiffness in Long Term Survivors of Childhood Cancer

Research

High-Risk and Low-Risk Human Papillomavirus in Esophageal Squamous Cell Carcinoma at Mazandaran, Northern Iran
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits